NEUTROPHIL/LYMPHOCYTE RATIO AND PLATELET/LYMPHOCYTE RATIO IN PATIENTS WITH NSCLC

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• The neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) are emerging biomarkers reflecting systemic inflammation.
• Assessing the prognostic value of these ratios in Non-Small-Cell Lung Cancer (NSCLC) is crucial for understanding disease severity.

Purpose of the Study:

• To compare NLR and PLR in NSCLC patients with and without metastases at diagnosis.
• To determine the potential of these ratios in evaluating NSCLC severity.

Main Methods:

• Retrospective analysis of NLR and PLR in 57 randomly selected NSCLC patients before anti-tumor treatment.
• Calculation of NLR and PLR from full blood count (FBC) data.
• Comparison of NLR and PLR values between patients with and without metastases using the Mann-Whitney U test.

Main Results:

• No significant difference was found in NLR between NSCLC patients with and without metastases (p = 0.614).
• Similarly, no significant difference was observed in PLR between the two groups (p = 0.068).
• The study included a total of 57 NSCLC patients, with data analyzed before any anti-tumor therapy.

Conclusions:

• Current findings suggest that NLR and PLR do not serve as reliable indicators for assessing NSCLC severity or the presence of metastases at diagnosis.
• While a link between immune status and cancer development is plausible, further extensive clinical and laboratory studies are required.
• More research is needed to elucidate the precise role of immune cells in cancer development and suppression.